SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-025252
Filing Date
2020-05-14
Accepted
2020-05-14 07:05:43
Documents
14
Period of Report
2020-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K 20Q1 EARNINGS RELEASE tcrr-8k_20200514.htm   iXBRL 8-K 38276
2 EX-99.1 tcrr-ex991_6.htm EX-99.1 303017
3 GRAPHIC grcxdq54s24h000001.jpg GRAPHIC 3561
  Complete submission text file 0001564590-20-025252.txt   496713

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tcrr-20200514.xsd EX-101.SCH 5760
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrr-20200514_lab.xml EX-101.LAB 20227
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrr-20200514_pre.xml EX-101.PRE 12072
9 EXTRACTED XBRL INSTANCE DOCUMENT tcrr-8k_20200514_htm.xml XML 3659
Mailing Address 100 BINNEY STREET CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET CAMBRIDGE MA 02142 617-949-5200
TCR2 THERAPEUTICS INC. (Filer) CIK: 0001750019 (see all company filings)

IRS No.: 474152751 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38811 | Film No.: 20875261
SIC: 2836 Biological Products, (No Diagnostic Substances)